Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZT002 DDI Study with Metformin, Warfarin, Rosuvastatin and Digoxin in Overweight/Obese Participants
NCT07550816Phase 1Active, not recruiting
- Sponsor
- QL Biopharm
- Start
- May 2026
- Primary completion
- Dec 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of zovaglutide in obesity (2 arms), sponsored by QL Biopharm. Primary endpoint: Area under the concentration-time curve. Started May 2026; status: active, not recruiting.
02
Drugs
zovaglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07550816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07550816.